CELLECTAR BIOSCIENCES INC

CLRBNASDAQ

🏆 #4822 by market capUS Equity

$418.53▲ $0.88 (+0.21%)

Simulated price

🔔

Track CLRB

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.2%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$17M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

189.0x

Expensive

Otter Score

Weak

No chart data available for CLRB.

Trading Snapshot

Day Range: $414.70 – $425.18
52-Week Range: $1.80 – $6.52
Volume: $1.72B
Avg Volume: $1.99B
Shares Outstanding: 8.0M
Next Earnings: Dec 3, 2026

Fundamentals Snapshot

Annual Revenue: $90,000
Last Q Revenue: $20,940
P/E Ratio: —
P/S Ratio: 189.0x
EPS (TTM): $-4.59
Dividend Yield: —
Dilution (1yr): +203.3%

Why Investors Own CLRB

✓High-growth profile — revenue up +48.2% YoY with expanding US Equity exposure.
✓Healthy economics — 31% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CELLECTAR BIOSCIENCES INC

CLRB

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$23M▼ −55.6% YoY

Free Cash Flow

−$23M▼ −51.5% YoY

Shares Outstanding

4.2M▲ +203.3% YoY

Net Cash

$13M▼ −$10M YoY

StockOtter · stockotter.space

About CELLECTAR BIOSCIENCES INC

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

🦦